Ozbaş-Turan S, Akbuğa J, Enneli B
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
Pharmazie. 2009 Dec;64(12):807-11.
The objective of this study was to investigate the effect of different formulation parameters [i.e. molecular weight and concentration of chitosan, concentration of tripolyphosphate (TPP) and use of alginate] on physico chemical and antisense properties of antisense oligonucleotide (AsODN) loaded chitosan nanoparticles (NPs). Preparation methods of phosphodiester (PO) and phosphorothioate (PS) AsODNs-NPs were also compared. AsODN was designed to target the beta-galactosidase (beta-gal) gene. HeLa cells were used for in vitro transfection studies and beta-gal was assayed spectrophotometrically. AsODN-NPs obtained were in general positively charged with size between 221.4-525.7 nm depending on formulation. Encapsulation efficiency of NPs depended on the type of backbone of the AsODN. PO-AsODN encapsulation into NPs (78-94%) was less efficient than PS encapsulation (91-98%). The pH of the chitosan solution affected AsODN entrapment. PO-NPs exhibited faster AsODN release than NPs containing PS. In general higher beta-gal inhibition was obtained after transfection of AsODN-NPs in cell culture studies. PS-NPs exhibited a higher inhibition effect and the highest (90.71%) inhibition was obtained with formulation PT-2. PS-adsorbed NPs showed an 88% reduction in beta-gal. This study can form the basis for forthcoming in vivo studies related to AsODN carrier systems that will use chitosan.
本研究的目的是调查不同配方参数[即壳聚糖的分子量和浓度、三聚磷酸钠(TPP)的浓度以及海藻酸盐的使用]对负载反义寡核苷酸(AsODN)的壳聚糖纳米颗粒(NPs)的物理化学性质和反义性质的影响。还比较了磷酸二酯(PO)和硫代磷酸酯(PS)AsODNs-NPs的制备方法。AsODN被设计用于靶向β-半乳糖苷酶(β-gal)基因。使用HeLa细胞进行体外转染研究,并通过分光光度法测定β-gal。所获得的AsODN-NPs通常带正电荷,其尺寸根据配方在221.4-525.7nm之间。NPs的包封效率取决于AsODN主链的类型。PO-AsODN包封到NPs中的效率(78-94%)低于PS包封(91-98%)。壳聚糖溶液的pH值影响AsODN的包封。PO-NPs比含PS的NPs表现出更快的AsODN释放。一般来说,在细胞培养研究中转染AsODN-NPs后获得了更高的β-gal抑制率。PS-NPs表现出更高的抑制效果,并且配方PT-2获得了最高(90.71%)的抑制率。PS吸附的NPs显示β-gal降低了88%。本研究可为即将开展的与使用壳聚糖的AsODN载体系统相关的体内研究奠定基础。